Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00598390 · ClinicalTrials.gov registry record · Phase 1
PET Imaging of Cannabinoid CB1 Receptors Using [11C]MePPEP
A Phase 1 study, sponsored by National Institute of Mental Health (NIMH).
- Completed
- Registry status
- Phase 1
- Development phase
- 19
- Enrollment target
NCT00598390 is a Phase 1 study that has completed, run by National Institute of Mental Health (NIMH). The registered enrollment target is 19 participants.
The verdict
NCT00598390, a Phase 1 study, has completed, sponsored by National Institute of Mental Health (NIMH).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 19 participants
- Enrollment target
Study Summary
The purpose of this protocol is to measure brain CB1 receptors in the hope to better understand how they work, so that one day we can understand how the CB1 receptors are involved in psychiatric, neurological, and behavioral disorders.
Interventions
- DRUG [11C]MePPEP
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2008-01-08 |
| Est. Completion | 2013-01-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00598390
The ClinicalTrials.gov registry entry for NCT00598390 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Mental Health (NIMH), which has 343 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which [11C]MePPEP is the first listed.
NCT00598390 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00598390 about?
NCT00598390 is a clinical study titled "PET Imaging of Cannabinoid CB1 Receptors Using [11C]MePPEP". The purpose of this protocol is to measure brain CB1 receptors in the hope to better understand how they work, so that one day we can understand how the CB1 receptors are involved in psychiatric, neurological, and behavioral disorders.
What is the current status of trial NCT00598390?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 19 participants. The study started on 2008-01-08. Estimated completion is 2013-01-22.
What interventions are being tested in trial NCT00598390?
The interventions under investigation include: [11C]MePPEP (DRUG).
Who is sponsoring clinical trial NCT00598390?
This trial is sponsored by National Institute of Mental Health (NIMH), which has 343 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.